Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 186

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 8
Chunk 186
---
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

    Page

    Report of Independent Registered Public Accounting Firm
    69

    Consolidated Balance Sheet as of December 31, 2024 and 2023
    70

    Consolidated Statement of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023
    71

    Consolidated Statement of Stockholders’ Deficit for the Years Ended December 31, 2024 and 2023
    72

    Consolidated Statement of Cash Flows for the Years Ended December 31, 2024 and 2023
    73

    Notes to Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023
    74

 68

Report of Independent Registered Public Accounting Firm 

To the Stockholders and Board of Directors 

MiNK Therapeutics, Inc.: 

Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of MiNK Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. 

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United